Yesterday
Episode 162: Head and Neck Cancer Series, Pt. 4 – Discussion with Radiation Oncology
This week the Head and Neck series turns to radiation oncology, with guest Dr. David Palma, a Professor and Radiation Oncologist at the Verspeeten Family Cancer Centre and professor at the Schulich School of Medicine and Dentistry, Western University (London, Ontario). A clinicia ... Show More
46m 24s
Aug 19
Episode 161: Career Development Series- Building a Career in Clinical Research
This week, we are so excited to share the third episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidan ... Show More
27m 42s
Aug 12
Episode 160: Head and Neck Cancer Series, Pt. 3 – Discussion with ENT
Throughout this series, we have discussed how multidisciplinary the management of head and neck cancer is and the critical role that our surgical colleagues play in the management of this disease. This week, we welcome Dr. Michael Topf, Associate Professor for Associate Professor ... Show More
36 m
Aug 2021
Latest Research on the Intensity of AML Therapy in Older Patients, Platelets and T cell Activity in Sepsis, and Genotyping for CNS Lymphoma
In this week's episode, we’ll start by reviewing an intriguing study that, while not randomized, calls into question whether less-intensive induction therapies provide a survival or quality of life benefit in older patients with AML. Next, we will review the somewhat surprising f ... Show More
19m 21s
May 2022
S1 Episode 2: Frontline Therapy for Multiple Myeloma
Joseph Mikhael, MD, and Peter Voorhees, MD, discuss frontline therapy for multiple myeloma and new options for both transplant-eligible and transplant-ineligible patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/view ... Show More
23m 37s
Nov 2021
Machine learning in classification of AML, aging bone marrow in leukemia, and treating bleeding disorders of unknown cause
In this week’s episode, we’ll learn more about the application of machine learning in molecular subclassification and prognostication of acute myeloid leukemia or AML, discuss the role of aging bone marrow in leukemia progression, and learn more about the challenges in treating b ... Show More
19m 25s
May 2025
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease
In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesios ... Show More
19m 58s
Oct 2024
254. Months of Monocytosis – An approach to CMML
Send us Fan MailIn this episode, we discuss the clinical presentation, work-up, and treatment of CMML. Our medicine minute discusses emerging evidence on the use of ruxolitinib for CMML treatment. Written by: Dr. Elliot Smith (Internal Medicine Resident)Reviewed by: Dr. Stephanie ... Show More
17m 17s
Sep 2025
S2 Episode 3: When Is the Best Time to Use CAR T-Cell Therapy in Multiple Myeloma?
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ... Show More
24m 38s
In today’s episode, we discuss how to approach AML treatment for patients who are unfit for intensive therapy.
Episode contents:
- How do we assess fitness for intensive AML?
- What are options for patients who are unfit for intensive chemotherapy for AML?
- What are important genetic mutations are important to check for?
- What are the key trials that inf ... Show More
